Sorafenib and FOLFIRI Regimen in 2nd Colorectal Cancer (CRC) After Failure of Oxaliplatin Treatment
Status:
Unknown status
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the Progression-Free Survival (PFS) time of
Sorafenib in combination with FOLFIRI regimen used as in the second front treatment in
patients with advanced CRC after failure of oxaliplatin treatment.